By David Wallace – Patient perspective | September 25, 2026 The established polycythemia vera hematocrit target is below 45%. That goal lowers the risk of serious blood clots and cardiovascular death. It does not necessarily mean symptom relief. I learned that the hard way. My circulation-related symptoms often started around 42%, well before I hit the […]
Mimrylo Earns NCCN Category 1 Recommendation for PV
By David Wallace – September 23, 2026 Mimrylo (rusfertide) has been added as a Category 1 treatment option for both low- and high-risk polycythemia vera (PV) in the National Comprehensive Cancer Network’s updated guidelines. For patients who need frequent phlebotomies, the update is another reason to ask whether a medicine designed to control hematocrit could […]
How I Achieved Complete Molecular Remission From Polycythemia Vera (PV)
by David Wallace, Founder, PV Reporter & MPN Cancer Connection When I was first diagnosed with polycythemia vera, nobody told me that PV remission was even possible. And the only treatment I was given, phlebotomy alone, guaranteed it wouldn’t be. Today, my blood counts are normal, and the molecular markers driving my PV are undetectable. […]
One Pill, Once a Day: FDA Approves Jakafi XR
Summary Ruxolitinib, the cornerstone treatment for myelofibrosis, polycythemia vera, and graft-versus-host disease, just got easier to take. On May 1, 2026, the FDA approved Jakafi XR™, a once-daily extended-release tablet formulation of the same proven drug. It will be available at pharmacies as early as May 8. Key Points Same medicine, simpler schedule: Jakafi XR […]
